계명대학교 의학도서관 Repository

Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents - The DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) Registry -

Metadata Downloads
Author(s)
Joo-Yong HahnYoung Bin SongJin-Ho ChoiSung-Hyuk ChoiSung Yun LeeHun Sik ParkSeung Ho HurSahng LeeKyoo-Rok HanSeung-Woon RhaByung Ryul ChoJong-Sun ParkJunghan YoonDo Sun LimSang Hoon LeeHyeon-Cheol Gwon
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
Circulation Journal
Issued Date
2010
Volume
74
Issue
11
Abstract
Background: The optimal duration of dual antiplatelet therapy remains controversial.
Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective
multicenter registry for 3-month dual antiplatelet therapy (aspirin 100–200 mg+clopidogrel 75 mg daily) followed
by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock,
stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48 h, previous drug-eluting stent implantation,
severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The
primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet
therapy was 95 days (interquartile range 90–101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients
(0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients
(0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free
at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than
3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR
0.90; 95%CI, 0.09–9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48–1.67) after adjustment for
the propensity score.
Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively
low-risk patients. (Circ J 2010; 74: 2314 – 2321)
Key Words: Antiplatelets; Drug-eluting stents
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Joo-Yong Hahn et al. (2010). Three-Month Dual Antiplatelet Therapy After Implantation of Zotarolimus-Eluting Stents - The DATE (Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent) Registry -. Circulation Journal, 74(11), 2314–2321. doi: 10.1253/circj.CJ-10-0347
Type
Article
ISSN
1346-9843
DOI
10.1253/circj.CJ-10-0347
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35433
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.